Navigation Links
PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
Date:11/20/2007

y's Quarterly Report on Form 10-Q for the period ended September 30, 2007 as filed with the SEC on November 7, 2007, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

Contacts:

Jennifer Baird,

Director of Public Relations

PAREXEL International

Tel: +781-434-4409

Email: Jennifer.Baird@PAREXEL.com

Rebecca Passo

SHIFT Communications

Tel : +617-779-1817

Email : rpasso@shiftcomm.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
7. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... SAN DIEGO, Aug. 4, 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: ... for the quarter ended June 30, 2011. (Logo: ... for the second quarter of 2011 of $24.2 million, or ... as compared to a net loss for the second ...
... Dehaier Medical Systems Ltd. (Nasdaq: ... in the development, assembly, marketing and sale of medical ... that it will release financial results for the second ... Monday, August 15, 2011 before the start of trading ...
Cached Medicine Technology:Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 2Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 3Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 4Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 5Dehaier Medical to Report Second Quarter 2011 Financial Results on August 15 2
(Date:4/18/2014)... (April 18, 2014) ― A new study in the ... patterns in health-related Google searches reveals a recurring pattern ... , Investigators from San Diego State University, ... Monday Campaigns, analyzed "healthy" Google searches (searches that included ... diet") originating in the U.S. from 2005 to 2012. ...
(Date:4/17/2014)... genetic variant specifically associated with the risk of ... per cent of all breast cancer cases. , ... sub-type, called invasive lobular carcinoma, gives researchers important ... kind of breast cancer, which can be missed ... in the journal PloS Genetics , was ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... Rochelle, NY, April 17, 2014U.S. military personnel who ... plus impact" concussive traumatic brain injury (TBI) were ... evacuated for other medical reasons. Differences in measures ... depression 6-12 months after injury are reported in ... a peer-reviewed journal from Mary Ann Liebert, Inc., ...
(Date:4/17/2014)... a new mechanism that allows blood to enter the ... and the Salk Institute have opened the door to ... damage. , A complex and devastating neurological condition, stroke ... for disability in the U.S. The blood-brain barrier is ... into the brain, causing the permanent deficits in movement ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... Jenifer Goodwin HealthDay Reporter , TUESDAY, Sept. 6 ... to fold laundry, mow the lawn or stand in line, ... bay. New research finds that seniors who expended the ... ones and simply going about their business were less likely ...
... , TUESDAY, Sept. 6 (HealthDay News) -- There,s no ... heart disease, says a study that challenges a long-held ... women spikes after menopause. Aging alone, not the ... deaths among older women, according to the Johns Hopkins ...
... Pediatric obesity ends up costing $3 billion annually in ... be saved by streamlining medical coverage to address health ... to treat conditions they develop as they get older, ... morbidly obese children, access to multidisciplinary services can lead ...
... Reporter , MONDAY, Sept. 5 (HealthDay News) -- An ... into the U.S. blood supply and doctors need to ... Babesiosis is a parasitic infection that is transmitted through ... range from mild flu-like symptoms to severe difficulty with ...
... at Columbia University,s Mailman School of Public Health heightens ... a group of ubiquitous chemicals known as phthalates. Phthalates ... disrupt the endocrine system, and are widely used in ... materials, to shampoos. Recent studies of school-age children ...
... Psychogenic non-epileptic seizures may go undiagnosed for much longer in ... in the September 6, 2011, print issue of Neurology ... This type of seizure is different from seizures related to ... "People with psychogenic seizures are often diagnosed with epilepsy and ...
Cached Medicine News:Health News:Routine Chores Might Help Keep Dementia at Bay 2Health News:Routine Chores Might Help Keep Dementia at Bay 3Health News:Routine Chores Might Help Keep Dementia at Bay 4Health News:Aging, Not Menopause, Raises Women's Heart Risks, Study Finds 2Health News:Study finds payment for pediatric obesity services now can save money later 2Health News:Tick-borne Illness May Lurk in Blood Supply 2Health News:Tick-borne Illness May Lurk in Blood Supply 3Health News:Prenatal exposure to phthalates linked to decreased mental and motor development 2Health News:Non-epileptic seizures may be misdiagnosed longer in veterans 2
... In the way it implements the ... 510 Meta system is unmatched. It allows ... compromising resolution and efficiency. Unprecedented flexibility for ... functions that guarantee fast and efficient structural ...
... first inverted microscope to take full advantage ... design enables optical input/output of light and ... and detector equipment. Extendable "Stratum Structure" configuration ... source and other attachments within the infinity ...
... with direct digital output. Three-chip color camera ... wide array of high-quality color video cameras ... flexibility you need for an efficient viewing ... real-time image of your specimen that can ...
... The PM30 is a premium photomicrography ... quality photomicrographs of even the most difficult ... the new PM30 system provide solution to ... addition to their automatic exposure control, the ...
Medicine Products: